The pathogenesis of infant acute lymphoblastic leukemia (ALL) is still not well defined. Short latency to leukemia and very high concordance rate for ALL in Mixed-Lineage Leukemia (MLL)-positive infant twins suggest that the MLL rearrangement itself could be sufficient for overt leukemia. Attempts to generate a suitable mouse model for MLL-AF4-positive ALL did not thoroughly resolve the issue of whether cooperating mutations are required to reduce latency and to generate overt leukemia in vivo. In this study, we applied single-nucleotide polymorphism array technology to perform genomic profiling of 28 infant ALL cases carrying t(4;11) to detect MLL-cooperating aberrations hidden to conventional techniques and to gain new insights into infant ALL pathogenesis. In contrast to pediatric, adolescent and adult ALL cases, the MLL rearrangement in infant ALL is associated with an exceptionally low frequency of copy-number abnormalities, thus confirming the unique nature of this disease. By contrast, additional genetic aberrations are acquired at disease relapse. Small-segmental uniparental disomy traits were frequently detected, mostly constitutional, and widely distributed throughout the genome. It can be argued that the MLL rearrangement as a first hit, rather than inducing the acquisition of additional genetic lesions, has a major role to drive and hasten the onset of leukemia.
Introduction
Acute lymphoblastic leukemia (ALL) occurring in children in the first year of their life ('infant ALL') is a rare but aggressive disease, with unique biological and clinical features. 1, 2 Rearrangements of the Mixed-Lineage Leukemia (MLL) gene on 11q23 represent a major genetic feature, with the t(4;11)/ MLL-AF4 fusion characterizing the largest subgroup. The eventfree survival of infant ALL is exceptionally low (45-50%), when compared with older children with ALL (B80%). 1, [3] [4] [5] [6] The MLL rearrangement as a first, prenatal leukemogenic event has been elegantly shown to occur in utero by Ford and colleagues. 7 Although the same is true for other types of leukemia, the far shorter latency to leukemia in infant ALL compared with older children, and the exceptionally high concordance rate for ALL in monochorionic twins, 8 indicate that the sole MLL fusion gene could be sufficient for overt leukemia development. Previous attempts to generate a suitable mouse model for MLL-AF4 leukemia failed to faithfully recapitulate the phenotype of pro-B ALL and the early onset observed in patients, 9, 10 suggesting that the MLL-AF4 fusion transcript alone is necessary but not sufficient enough to generate leukemia, and that additional mutations might be required. Along with this hypothesis, it has been shown that leukemia onset in mice can be accelerated if a transforming MLL fusion gene is cotransfected into stem cells along with the FLT3 activating mutation. 11 However, candidate secondary mutations that might be responsible for cancer have not been found in these studies. 9 More recently, Krivtsov et al. 12 have reported the development of a mouse model of MLL-AF4 on the basis of conditional knockin strategy which rapidly induces ALL (or acute myelogenous leukemia) with features similar to the human disease, thus implying that MLL-AF4 as single oncoprotein is responsible for inducing specific epigenetic changes and altering gene expression which lead to overt leukemia.
Recently, many genome-wide single-nucleotide polymorphism (SNP) array studies on childhood ALL (range: 1-18 years) identified deletions at several loci, mainly affecting genes that have a critical role in regulating B-cell development and differentiation. [13] [14] [15] These findings suggested that the direct disruption of pathway(s) controlling B-cell development and differentiation contribute to BCP (B-cell precursor) ALL pathogenesis. 13 In addition, a similar pattern of deletions was also observed in adult and adolescent ALL, 16 suggesting that microdeletions that affect key genes may be a common trademark of ALL despite age, clinical, morphological, and cytogenetic differences. These results also highlight the power of high-resolution genome-wide approaches to identify new molecular lesions in cancer. In fact, the recently introduced SNP array technology represents the implementation and evolution of cytogenetics toward the detection of submicroscopical lesions, the major advantages residing in the uniform and high-density distribution of polymorphic sequences across the whole genome. SNPs are used to search for loss-of-heterozygosity (LOH) regions in cancer, resulting in an allelic imbalance. LOH can be distinct in copy-number abnormalities (CNAs), such as deletions or amplifications, and uniparental disomy (UPD). The latter can originate from a number of different mechanisms, such as trisomic rescue, non-disjunction, compensation of an abnormal chromosome, or mitotic recombination, which result in the loss of one parental allele and duplication of the other, leading to the detection of a copy-number neutral state of LOH. 17 UPD is an emerging finding in both ALL and acute myelogenous leukemia patients, for whom it has been associated with homozygous gene mutations sustaining disease progression and chemoresistance. 16, [18] [19] [20] Nevertheless, extended runs of homozygosity (ROH) have been found in normal individuals, [21] [22] [23] resulting from different degrees of inbreeding. ROHs among unrelated patients lead to the identification of new genes or candidate loci responsible for the genetic basis of the disease. [23] [24] [25] In this study, we explored the genomic profile of infant ALL by SNP array to detect MLL-cooperating aberrations, hidden to conventional techniques. To further limit heterogeneity, we focused on patients carrying the t(4;11) translocation, which is the most frequent genetic abnormality in infant ALL. Our final intention was to acquire new insights into the pathogenesis of this rare and aggressive leukemia, in addition to establishing a platform to search for novel candidates for targeted therapy.
Materials and methods

Patients and samples
Bone marrow or peripheral blood aspirates were collected from 28 cases of infant ALL with t(4;11)/MLL-AF4 at the time of diagnosis. The paired samples at remission and relapse were available for 18 and 8 out of 28 cases, respectively. The study was approved by the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) Infant Scientific Committee. Infants were enrolled in the Interfant-99 and Interfant-06 International Treatment Protocols for infant ALL. 3 The initial diagnosis was based on standard morphological, cytochemical and immunophenotypic criteria. All patients showed a pro-B immunophenotype, with blasts lacking CD10 expression at diagnosis; the median age was 5.0 months (range: 1.0-11.5); 14 patients were male and 14 were female. The vast majority showed hyperleukocytosis, with the median white blood cell count of 343 340 cells per ml (range: 14 900-994 000). Cytogenetic and fluorescent in situ hybridization analyses were carried out whenever samples were available (MLL split-apart fluorescent in situ hybridization probe, DakoCytomation, Glostrup, Denmark), and fusion gene transcripts were detected in all cases by reverse transcriptase-PCR on RNA isolated using the GeneElute Mammalian Total RNA Isolation Kit (Sigma, St Louis, MO, USA). Hematological remission and relapse were defined when at least 5 or 25% of blast cells were detected by morphological examination, respectively.
SNP arrays
Genomic DNA from mononuclear cells (freshly isolated by Ficoll-Paque density gradient centrifugation) was extracted using DNA Purification System Blood Kit (Gentra Systems, Minneapolis, MN, USA) and prepared for GeneChip Human Mapping 100K Array analysis according to the manufacturer's instructions (Affymetrix Inc., Santa Clara, CA, USA). Briefly, genomic DNA was digested in parallel with Xba and Hind restriction enzymes, ligated to an adaptor and subsequently amplified by PCR with adaptor-specific primers. PCR products were purified, fragmented with DNase I (Affymetrix), biotin labeled and then hybridized onto the microarray. Washing and staining of GeneChip Mapping probe arrays was performed automatically in Affymetrix Fluidics Station 450/250, and the chips were scanned using the GeneChip Scanner 3000 at the facility of the 'Genopolis' Consortium (University of MilanBicocca, Milan, Italy). Microarray data are deposited in the ArrayExpress repository (accession number: E-TABM-511).
CNA and LOH analyses
The 100K SNP arrays raw data were acquired using the Affymetrix GCOS software (version 1.4), and SNP calls were generated by the GTYPE software (Affymetrix, version 4.0). CN and LOH analyses were carried out in parallel with dChip2007 (http://biosun1.harvard.edu/complab/dchip/manual.htm) and CNAG2.0 (Copy Number Analyzer for GeneChip Mapping 100K arrays, http://www.genome.umin.jp) software according to the manufacturers' instructions, by combining the two data sets from GeneChip Human Mapping 50K Xba and 50K Hind arrays. In both analyses, infant ALL samples were compared with publicly available normal reference including 60 Mapping 100K SNP parents of trio CEU HapMap data set (http:// www.hapmap.org). The detailed method and bioinformatic analyses are reported in Supplementary Text. Using the UCSC Genome Browser database (http://genome.ucsc.edu), genes were assigned to the aberrant regions according to the hg16 release (14 May 2008) . For direct comparison with older childhood BCP-ALL cases, infant ALL cases were analyzed together with the 100K SNP array data subset of BRC-ABL (n ¼ 9) and ETV6-RUNX1 (n ¼ 47) samples from the study by Mullighan et al. 13 In addition, each segmental UPD region was compared with ROH segments recently identified using SNP array 250K technology in a large cohort of 144 unrelated healthy individuals from an outbred Caucasian population as reported in Lencz et al.
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Direct sequencing
Genomic sequences including specific SNP sites were amplified by PCR (specific primer pairs are indicated in Supplementary  Table 1) , and clonal PCR products were directly sequenced to confirm the SNP homozygous/heterozygous status detected by SNP array. DNA from six aged-matched healthy newborns (aged o1 year) was used as a control for sequencing.
Gene expression analysis
Total RNA was extracted from stored cryopreserved infant ALL specimens using TRIzol (Invitrogen, Carlsbad, CA, USA), followed by a purification step (RNeasy Mini Kit, Qiagen, Hilden, Germany) and microarrays analyses were carried out using Human Genome U133 Plus 2.0 GeneChip Array (Affymetrix) as described in Zangrando et al. 26 Microarray raw data are available online at the Gene Expression Omnibus (GEO) repository (accession number: GSE14062).
Results
In this study, we present a genome-wide copy-number analysis of 28 infant ALL patients with t(4;11)/MLL-AF4 at diagnosis, and their matched samples at remission and relapse when available. This is the first report that encompasses such a sizable cohort of patients below 1 year of age affected by this rare and aggressive disease. Previously, other authors reported pediatric, adolescent or adult cases ( Compared with other ALL subgroups, infant ALL with the MLL rearrangement show an exceptionally low frequency of CNA Compared with published data in older (41 year) ALL patients, a far limited number of deletions/amplifications have been found in infant ALL (Table 1) . Among all the patients analyzed, a total of only 6 CNAs were detected at diagnosis, occurring in 5 of 28 (14)(q21.3)) were detected in pt.22, the somatic or constitutional nature of which was not defined because of the unavailability of the corresponding remission sample. The large del(3)(p11.1 p12.2) found in pt.14 was not tumor associated, as it was detected in both diagnostic and remission phases (Supplementary Table 2 ).
To directly compare infant samples with older BCP-ALL patients, we took advantage of the recent data published by Mullighan et al. 13 on a large cohort of childhood ALL. For consistency, we reanalyzed by dChip the 100K SNP array data subset (out of the 350K performed) from Mullighan, together with our infant ALL 100K data (see the 'Materials and methods' section). Unlike BCR-ABL-and ETV6-RUNX1-positive samples, infant MLL-AF4 patients did not show any structural variation in the chromosomal regions commonly found in human leukemias, involving genes with a crucial role in B-cell development (Figure 1 ).
Additional CNA in infant ALL at relapse DNA from relapse samples was available for eight patients. In all cases, the CNAs detected in the diagnostic samples were still persistent at relapse (del(1)(p36.31p36.33) in pt.9, del(8)(q24.11) and del(14)(q21.3) in pt.22) ( Table 2 and  Supplementary Table 2 ). Interestingly, the loss of the whole p arm of chromosome 7 was identified as an additional and recurrent new lesion in 3 out of 8 relapse cases (pt.9, 21 and 22); in 2 of them it was associated with duplication of the whole q arm of chromosome 7 (iso(7q)). Moreover, patient 22 also presented additional trisomy of chromosome 8 ( Figure 2 and Supplementary Figure 1) .
Seven additional UPDs, undetected at diagnosis and/or at remission, were identified at relapse in two out of eight cases (pt.2, 3 and 10) (Supplementary Table 2 ).
Constitutional UPD in infant ALL
A total of 122 events of UPD were identified among the 28 infant ALL patients, accounting for 98 single regions, widely distributed throughout the genome and variable in size from 150 kb to 38 Mb (Supplementary Tables 2-4 , and Supplementary Figure 2) . In most of the cases (63 of 122), the UPDs were constitutional (not tumor associated), being detected at both diagnostic and remission phases, whereas only a small subset (20 of 122) was tumor-associated somatic lesions. For the remaining 39 cases, the remission sample was not available for analysis. Among the regions larger than 1 Mb, we identified 12 recurrent UPDs, defined as present in at least 2 diagnostic samples (Table 3 and Supplementary Table 5 ). To confirm the stretches of homozygosity, we investigated the homozygous/ heterozygous status of several SNPs mapping within some of the UPD regions (Supplementary Figures 3-6 ). Selected SNPs with the highest frequency of heterozygosity were directly sequenced on PCR amplification of diagnostic and remission samples and compared with six aged-matched healthy newborns (aged o1 year), which also served as a further control for SNP array LOH analysis. By sequencing, we confirmed the homozygous status of infant ALL patients under investigation compared with normal heterozygous controls.
To investigate the nature of these homozygous traits, the genomic UPD regions were compared with the ROH data set recently described in a large cohort of unrelated healthy individuals. 23 We found that 4 out of 12 regions extensively overlapped (425%) with known ROH regions, 2 overlapped only partially (o10%), whereas 6 segments were not overlapping with any known ROH. Among these, the UPD(14) (q21.2), including the FANCM (Fanconi's anemia complementation group M) gene, was the most recurrent, being detected in four cases (pt.3, 4, 8 and 21) ( Table 3) . A further sequence analysis of the FANCM coding sequence confirmed the homozygous status of the 18 coding SNPs in the 4 patients carrying the UPD(14)(q21.2) (data not shown). However, no oncogenic mutations were found. In addition, levels of expression of FANCM or other genes involved in the Fanconi's anemia-related DNA-repair pathway (as BRCA1, BRCA2/FANCD1 and RAD51) were similar in the investigated infant ALL patients, regardless of the presence of UPD(14)(q21.2) (data not shown).
Discussion
This study focused on the genomic profiling of infant ALL patients carrying the t(4;11) translocation, the most frequent aberration in infant ALL, 1 with the aims to: (1) search for The precise number on CNA was not reported, although the overall results are similar to Mullighan et al. Unique genotype of infant ALL M Bardini et al candidate cooperative genomic lesions, which might be hidden to conventional techniques, and (2) compare the infant ALL genomic profile with other known ALL age groups. The most striking observation was the absence of leukemia-associated secondary genetic aberrations observed in infant ALL. This is in extreme contrast to recent findings in older patients, strongly Figure 1 Heatmap of copy-number abnormality (CNA) in infant acute lymphoblastic leukemia (ALL) versus older childhood ALL. Loss-ofheterozygosity (LOH) analysis was performed by dChip software on infant ALL diagnostic samples (n ¼ 28) and childhood ALL samples compared with BCR-ABL (n ¼ 9)-or ETV6-RUNX1 (n ¼ 47)-positive cases from Mullighan's data set. 13 Only 100K single-nucleotide polymorphism (SNP) array data were analyzed for each subgroup. The plot shows a selection of 12 chromosome regions containing genes relevant to the B-cell differentiation pathway (on the left) and reported to be affected by CNA in childhood ALL by Mullighan et al. 13 Rows represent chromosome regions and columns represent samples. The CN value is displayed ranging from white (o2, deletion) to pink (2, diploid), to red (42, amplification).
Unique genotype of infant ALL
M Bardini et al confirming the uniqueness of this disease. In fact, SNP array studies in childhood, adolescent and adult ALL indicated that different genes along the same pathway can be deleted, and that the accumulation of their abnormalities could lead to frank malignancy, [13] [14] [15] [16] pointing to microdeletions of key genes as a general feature peculiar to BCP-ALL, shared among different Figure 2 Additional chromosomal lesion at relapses. Copy Number Analyser for GeneChip (CNAG) visualization of additional copy-number abnormality (CNA) detected in the relapse samples. The deletion of chromosome 7p was observed at relapse in 3 out of 8 samples (pt.9, 21 and 22) as a new lesion, not seen at diagnosis. In 2 cases (pt.21 and 22) it was associated with amplification of 7q (Iso(7q)). Pt. 22 also presented trisomy of chromosome 8. A log2 copy number ratio ¼ 0 indicates copy number 2n, 1 is for copy number 2n þ 1, whereas À1 is for copy number 2nÀ1. Green bars: heterozygous single-nucleotide polymorphism (SNP) calls referred to pooled references. Pink bars: discordant SNP calls of the diagnostic sample when compared with the pooled references. Cyan blue line: copy-number loss (deletion). Red pink line: copy-number gain (amplification). Blue line: loss-of-heterozygosity (LOH) likelihood. Female.
Unique genotype of infant ALL M Bardini et al age, clinical, morphological and cytogenetic subgroups. It has been shown that for most cases of leukemia, the initial transforming event alone is not sufficient to induce overt leukemia. 8 Although t(12;21)/ETV6-RUNX1Fthe most frequent rearrangement of childhood leukemia (25%)Foccurs in utero, children develop leukemia after the accumulation of multiple hits, which may also occur after several years. In addition, a consistent part of healthy individuals (1%) carries the translocation but never develops leukemia. 8 This is not the case for t(4;11)/MLL-AF4 ALL, whereby the pathogenetic mechanism(s) is likely to be different.
The 100K SNP array platform used in this study has a median intra-markers resolution of 22.5 Kb, lower than that of other studies (Table 1) . Although it can be argued that the low resolution of the SNP array platform could fail in detecting CNA, on the contrary, several arguments sustain that the sensitivity of the method applied in this study does not impair the results: (1) large CNAs were observed at the relapse phase; (2) the same platform was recently used in a subgroup of older childhood ALL, 27 allowing us to identify the same CNA detected by other groups with higher resolution; [13] [14] [15] [16] (3) the comparison of our infant ALL 100K data set with Mullighan's 100K subset (same resolution), further showed that the genotypic profile of infant and older childhood ALL subgroups are different (mean CNA in infant MLL-AF4 ¼ 0.2 versus mean CNA in ETV6-RUNX1 ¼ 6.0 and mean CNA in BCR-ABL ¼ 4.2 in Mullighan et al.); (4) the frequency of CNA calculated in this study resulted to be similar to that observed using a SNP platform with higher sensitivity by Mullighan et al. in a limited series of 11 MLL-positive cases (Table 1 and Mullighan et al.
13
), although the age of the patients and the identity of the MLL partner genes were not clearly defined in that study; (5) in a subset of 7 infant ALL diagnostic samples of this study, we carried out a more dense SNP analysis using the 250K SNP array technology and confirmed the results obtained by the 100K platform, both for CNA and for UPD (data not shown); (6) finally, the SNP array resolution applied in this study allowed us to detect deletions associated with the somatic rearrangement of Immunoglobulin/T-cell Receptor genes, although not included in the analysis of results, because of their irrelevance to the study. However, as a technical limitation of the method applied, we cannot exclude the presence of balanced chromosomal abnormalities or very small CNA, as well as point mutations.
On the other hand, new CNAs were found at relapse, thus confirming that the leukemic clone underwent a clonal evolution by acquiring additional aberrations during the clinical course of the disease. Therefore, in infant ALL, the accumulation of CNA seems to be related to the evolution and progression of the disease, rather than to its first occurrence. This is in agreement with recently published data on a large cohort of 61 diagnostic/relapse-matched ALL pediatric samples showing that more than 80% of relapse clones represent the evolution from either the diagnostic or the ancestral clone. 28 Several constitutional (not tumor-associated) segmental UPD regions have been detected in infant ALL patients, but not in normal newborns (aged o1 year), with the UPD(14)(q21.2) as the most recurrent. As UPD has been proposed to be a selective mechanism involved in leukemogenesis, [18] [19] [20] we investigated whether it could be responsible for the duplication of oncogenic mutations. Sequencing of the whole coding region of the FANCM gene in patients with UPD(14)(q21.2), although confirming the homozygous status of all the SNPs contained in the sequence, did not reveal any mutations. In addition, the possibility that UPD could lead to a deregulation of gene expression by epigenetic mechanisms (such as methylation) has been excluded by gene expression analysis of candidate genes. Hence, the significance of the constitutive 'non-ROH' segmental UPD traits found in infant ALL patients and whether they could have a role in the leukemogenic progress still remain to be determined. Indeed, extended 'runs of homozygosity' in the human genome have been found not only in patients [21] [22] [23] but also in healthy individuals; [23] [24] [25] therefore, UPDs could represent previously undetected new ROH, which are not involved in the pathogenesis of the disease. Conversely, it cannot be excluded that genomic background, characterized by constitutional stretches of homozygosity, might offer a permissive environment for the development of the disease, favoring the occurrence of the MLL rearrangement itself, although further work is required to explore this hypothesis.
In conclusion, the absence of secondary deletions, together with the evidences that the MLL rearrangement occurs in utero 7, 8 and the ascertained deregulatory effect of MLL-AF4 on target genes expression, 2, 12, 29 point out that MLL rearrangement per se, as a first and sole hit, has a major role in driving and hastening the leukemogenetic process.
